Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Puretech Health

Evaluate

Thumbnail
February 15, 2023

Spotlight – still plenty of hopefuls in lung fibrosis

Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.

Thumbnail
October 07, 2022

Nektar and Puretech make strange bedfellows

It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.

Article image
Vantage logo
November 18, 2019

Puretech’s cautionary tale about pivotal study read-across

The healthcare company builder Puretech registers one success and one failure, both underlining the need for robust mid-stage data.

Article image
Vantage logo
April 24, 2019

Gamma-delta work makes cautious inroads into the clinic

Article image
Vantage logo
January 28, 2019

Exosomes start to deliver deals

Article image
Vantage logo
November 29, 2018

FDA decision time looms for Gelesis

Gelesis’s weight-loss capsule only hit one of the two co-primary endpoints in its approval trial. Will the FDA be persuaded?

Article image
Vantage logo
July 20, 2018

Gamma-delta follows financing with consolidation

A new cell therapy approach has, in low-key fashion, attracted financing and the attention of big biopharma.

Article image
Vantage logo
July 16, 2018

Why Immatics could soon become the next listed cell therapy player

Immunocore and Adaptimmune could shortly have a publicly listed rival.

Vantage logo
January 02, 2018

Pharma news over the Christmas period 2018

Article image
Vantage logo
December 08, 2017

CAR-T: the next generation

The next generation of CAR-T therapies is already emerging.

Vantage logo
October 24, 2017

Interview – Syncona’s uncompromising message to the European markets

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up